GO
Loading...

Medicine

More

  • Sept 15- Avanir Pharmaceuticals Inc said its drug was more effective in reducing agitation associated with Alzheimer's, compared with a placebo, sending the company's shares up 55 percent to an over eight-year high.

  • *Gilead plans to sell Sovaldi in India for $300 a month. NEW DELHI/ MUMBAI, Sept 15- U.S. drugmaker Gilead Sciences Inc has licensed its hepatitis C drug Sovaldi to seven India- based drugmakers that will sell far cheaper versions of the $1,000- a-pill medicine in 91 developing nations.

  • Sept 15- Avanir Pharmaceuticals Inc said its drug was more effective in reducing agitation associated with Alzheimer's, compared with a placebo. The results from the mid-stage study pushed the company's shares up 28 percent before the bell.

  • *Acceptance for filing with priority review of supplemental new drug application for Vyvanse capsules for adults with binge eating disorder. *FDA is expected to provide a decision in February 2015, based on anticipated prescription drug user fee act action date. *Vyvanse should only be used to treat ADHD.

  • *Gilead plans to sell Sovaldi in India for $300 per month. NEW DELHI/ MUMBAI, Sept 15- U.S. drugmaker Gilead Sciences Inc has agreed to license its hepatitis C drug Sovaldi to seven India- based drugmakers to sell cheaper versions of the $1,000- a-pill medicine in 91 developing nations including India.

  • Gilead to license generic version of Sovaldi Monday, 15 Sep 2014 | 7:40 AM ET

    Gilead Sciences has reached a deal with several generic drugmakers to produce a cheaper version of its popular, $1,000- per-pill hepatitis C drug Sovaldi for use in developing countries.

  • Kids' poisonings linked to anti-addiction medicine Monday, 15 Sep 2014 | 12:01 AM ET

    CHICAGO— An anti-addiction drug used to fight the nation's heroin and painkiller abuse epidemics poses a threat to young children who accidentally swallow relatives' prescriptions, a federal study says.

  • LOS ANGELES, Sept 12- The next generation version of Gilead Sciences Inc's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.

  • The candidate Ebola vaccine is being co-developed by the United States National Institutes of Health and the British drugmaker GlaxoSmithKline. The trial will be led by Professor Adrian Hill of the Jenner Institute at Oxford University, which said on Friday the first shot is scheduled to be given to a human volunteer next week.

  • Sept 12- Eli Lilly and Co's Cyramza stomach-cancer drug prolonged survival of patients with advanced colon cancer in a late-stage study, the U.S. drugmaker said on Friday. The 1,000- patient global study, called RAISE, involved patients who had previously failed to adequately benefit from Roche Holding AG's Avastin and other standard treatments.

  • Lilly cancer drug fares well in late-stage study Friday, 12 Sep 2014 | 10:38 AM ET

    INDIANAPOLIS— Eli Lilly and Co. said Friday its potential colorectal cancer drug Cyramza helped patients on chemotherapy with advanced cases of the disease survive longer than patients on chemotherapy alone.

  • WASHINGTON, Sept 11- Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. It would be sold under the name Saxenda if approved for obesity by the FDA.

  • FDA panel backs Novo Nordisk injection for obesity Thursday, 11 Sep 2014 | 4:16 PM ET

    The FDA first approved the drug, liraglutide, under the brand name Victoza in 2010 as a daily injection for type 2 diabetes, in which the body does not properly use insulin. Danish drugmaker Novo Nordisk now wants the FDA to approve the drug as an obesity treatment based on company studies showing significant weight loss in most patients.

  • WASHINGTON, Sept 11- Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

  • FDA PANEL SAYS NOVO NORDISK'S LIRAGLUTIDE IS SAFE AND EFFECTIVE FOR CHRONICALLY OBESE PATIENTS.

  • JPM's Dimon finishes cancer treatments: Report Thursday, 11 Sep 2014 | 1:09 PM ET
    Jamie Dimon

    Jamie Dimon, who was diagnosed with throat cancer this year, finished his scheduled rounds of radiation and chemotherapy treatment, WSJ reported.

  • Sept 11- JPMorgan Chase& Co CEO Jamie Dimon, who was diagnosed with throat cancer this year, finished his scheduled rounds of radiation and chemotherapy treatment this week, the Wall Street Journal said, citing people familiar with the matter.

  • FDA approves weight-loss drug Contrave Thursday, 11 Sep 2014 | 6:53 AM ET

    Contrave joins two similar drugs from Arena Pharmaceuticals and Vivus Inc. which FDA approved in 2012 after a 13- year drought of new prescription weight-loss medicines. But sales of Vivus' Qsymia and Arena's Belviq have been far below expectations due to limited insurance coverage and high out-of-pocket costs for patients.

  • Sept 11- Ebola is just one of many neglected tropical diseases that badly need attention. The World Health Organization in 2012 designated 17 diseases as priorities for eradication or control:. There is no approved drug but the first vaccine from Sanofi could reach the market late next year.

  • The worst-ever Ebola outbreak, which has already killed at least 2,296 people in West Africa, has triggered a scramble to develop the first drug or vaccine for a deadly disease that was discovered nearly 40 years ago in the forests of central Africa.